The startup develops targeted genetic therapies utilizing engineered viruses and viral vectors to deliver genes directly to specific cells, enabling oncolytic virotherapy and in vivo gene editing. This technology provides clinicians with effective treatment options for various cancer indications, both as standalone therapies and in combination with immune-oncology drugs.
Funding
$99.6M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancers lack effective treatment options, especially in cases of advanced, relapsed, or refractory tumors. Traditional cancer therapies often fail to completely eradicate tumors or can cause significant off-target toxicities. There is a need for more targeted and effective therapies that can selectively destroy cancer cells while stimulating a durable anti-tumor immune response.
Solution
Vyriad is developing targeted genetic therapies using engineered oncolytic viruses to selectively infect and destroy cancer cells. The company's viral platforms, based on vesicular stomatitis virus (VSV) and measles virus, are engineered to target specific cancer types, maximize immune-enhancing properties, and minimize harm to normal cells. These oncolytic viruses utilize a dual killing mechanism, directly lysing tumor cells and stimulating the body's immune system to attack remaining cancer cells. Vyriad's approach combines preclinical development, GMP manufacturing, and clinical expertise to create tailored viral delivery solutions for in vivo gene therapy, gene editing, and oncolytic virotherapy.
Target Audience
Vyriad's therapies target patients with advanced, relapsed, or refractory solid tumors across various cancer indications, as well as pharmaceutical companies and medical institutions seeking innovative cancer treatment solutions.
Features
- Engineered oncolytic viruses based on VSV and measles platforms for targeted cancer cell infection and destruction
- Dual mechanism of action: direct tumor lysis and stimulation of anti-cancer immune responses
- Viral vectors optimized for cell-specific targeting, stability, and efficiency
- Clinical programs cover all phases of development, from Phase 1 to Phase 2 trials
- Clinical trials evaluating oncolytic virotherapies as monotherapies and in combination with immunotherapies
- GMP-certified manufacturing facility for producing clinical-grade oncolytic viruses
- Proprietary theranostic tests to predict patient responsiveness to oncolytic virotherapy
- Collaborative approach integrating R&D, manufacturing, and clinical expertise